tiprankstipranks
Trending News
More News >

NurExone Reports Breakthrough in Vision Restoration

Story Highlights
NurExone Reports Breakthrough in Vision Restoration

EnerSpar Corp. (TSE:NRX) has released an update.

Confident Investing Starts Here:

NurExone Biologic Inc. has reported promising preclinical results for its drug ExoPTEN, which shows potential in repairing optic nerve damage and restoring vision, particularly for conditions like glaucoma. The study revealed significant recovery in retinal activity and survival of retinal ganglion cells, highlighting ExoPTEN’s transformative potential in treating vision loss. These findings mark an important step in developing regenerative therapies that could impact millions of patients worldwide.

For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App